1. No category

PRESS RELEASE
Phase Holographic Imaging PHI AB (publ)
Org.nr. 556542-7811
Phase
Holographic Imaging
2015-10-05
Big Pharma embraces HoloMonitor technology from Phase Holographic Imaging
Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world
has decided to acquire two HoloMonitor® instruments. The ordered configuration is an automated version of the HoloMonitor platform. The total retail price of the orders amounts to €60 000.
“The pharmaceutical industry uses what is known in the industry as high-content screening to select drug candidates
from several 100 000 chemical substances. The orders from the leading Swiss pharma company are tremendously
important for the company’s future and confirm the potential of HoloMonitor technology in high-content screening.
Valuable feedback from the pharma industry will enable us to further improve our proprietary technology for more realistic
drug characterization. Various reports value the global high-content screening market to 500-1 100 million USD annually”,
said CEO Peter Egelberg.
For more information regarding high-content screening see http://www.phiab.se/commentary/commentary-151002.
Market reports
• Markets & Markets: http://www.marketsandmarkets.com/PressReleases/high-content-screening-market.asp
• Future Market Insights: http://www.futuremarketinsights.com/reports/high-content-screening-market
For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: peter.egelberg@phiab.se
Web: www.phiab.se
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and
software. With the first instrument introduced in 2011, the company today offers a range of products for long-term
quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains.
Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the
science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in
cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and
toxicological studies.
1/1